|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gholipour C, Shalchi RA and Abbasi M: A
histopathological study of esophageal cancer on the western side of
the Caspian littoral from 1994 to 2003. Dis Esophagus. 21:322–327.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pickens A and Orringer MB: Geographical
distribution and racial disparity in esophageal cancer. Ann Thorac
Surg. 76:S1367–S1369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen MF, Yang YH, Lai CH, Chen PC and Chen
WC: Outcome of patients with esophageal cancer: A nationwide
analysis. Ann Surg Oncol. 20:3023–3030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smyth EC, Lagergren J, Fitzgerald RC,
Lordick F, Shah MA, Lagergren P and Cunningham D: Oesophageal
cancer. Nat Rev Dis Primers. 3:170482017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhat M, Robichaud N, Hulea L, Sonenberg N,
Pelletier J and Topisirovic I: Targeting the translation machinery
in cancer. Nat Rev Drug Discov. 14:261–278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spilka R, Ernst C, Mehta AK and Haybaeck
J: Eukaryotic translation initiation factors in cancer development
and progression. Cancer Lett. 340:9–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aitken CE and Lorsch JR: A mechanistic
overview of translation initiation in eukaryotes. Nat Struct Mol
Biol. 19:568–576. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hinnebusch AG and Lorsch JR: The mechanism
of eukaryotic translation initiation: New insights and challenges.
Cold Spring Harb Perspect Biol. 4:a0115442012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Donzé O, Jagus R, Koromilas AE, Hershey JW
and Sonenberg N: Abrogation of translation initiation factor eIF-2
phosphorylation causes malignant transformation of NIH 3T3 cells.
EMBO J. 14:3828–2834. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shahbazian D, Parsyan A, Petroulakis E,
Topisirovic I, Martineau Y, Gibbs BF, Svitkin Y and Sonenberg N:
Control of cell survival and proliferation by mammalian eukaryotic
initiation factor 4B. Mol Cell Biol. 30:1478–1485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bitterman PB and Polunovsky VA:
eIF4E-mediated translational control of cancer incidence. Biochim
Biophys Acta. 1849:774–780. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bao Y, Lu Y, Wang X, Feng W, Sun X, Guo H,
Tang C, Zhang X, Shi Q and Yu H: Eukaryotic translation initiation
factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer
through epithelial mesenchymal transition. Cancer Cell Int.
15:1092015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wolfe AL, Singh K, Zhong Y, Drewe P,
Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van
der Meulen J, et al: RNA G-quadruplexes cause eIF4A-dependent
oncogene translation in cancer. Nature. 513:65–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meijer HA, Kong YW, Lu WT, Wilczynska A,
Spriggs RV, Robinson SW, Godfrey JD, Willis AE and Bushell M:
Translational repression and eIF4A2 activity are critical for
microRNA-mediated gene regulation. Science. 340:82–85. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chan CC, Dostie J, Diem MD, Feng W, Mann
M, Rappsilber J and Dreyfuss G: eIF4A3 is a novel component of the
exon junction complex. RNA. 10:200–209. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Q, Imataka H, Morino S, Rogers GW Jr,
Richter-Cook NJ, Merrick WC and Sonenberg N: Eukaryotic translation
initiation factor 4AIII (eIF4AIII) is functionally distinct from
eIF4AI and eIF4AII. Mol Cell Biol. 19:7336–7346. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wilczynska A, Gillen SL, Schmidt T, Meijer
HA, Jukes-Jones R, Langlais C, Kopra K, Lu WT, Godfrey JD, Hawley
BR, et al: eIF4A2 drives repression of translation at initiation by
Ccr4-Not through purine-rich motifs in the 5′UTR. Genome Biol.
20:2622019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang S, Zhou Y, Chen Y, Ke G, Wen H and
Wu X: Decreased expression of EIF4A1 after preoperative
brachytherapy predicts better tumor-specific survival in cervical
cancer. Int J Gynecol Cancer. 24:908–915. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lomnytska MI, Becker S, Gemoll T, Lundgren
C, Habermann J, Olsson A, Bodin I, Engström U, Hellman U, Hellman
K, et al: Impact of genomic stability on protein expression in
endometrioid endometrial cancer. Br J Cancer. 106:1297–1305. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Modelska A, Turro E, Russell R, Beaton J,
Sbarrato T, Spriggs K, Miller J, Gräf S, Provenzano E, Blows F, et
al: The malignant phenotype in breast cancer is driven by
eIF4A1-mediated changes in the translational landscape. Cell Death
Dis. 6:e16032015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oblinger JL, Burns SS, Akhmametyeva EM,
Huang J, Pan L, Ren Y, Shen R, Miles-Markley B, Moberly AC,
Kinghorn AD, et al: Components of the eIF4F complex are potential
therapeutic targets for malignant peripheral nerve sheath tumors
and vestibular schwannomas. Neuro Oncol. 18:1265–1277. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan K, Robert F, Oertlin C,
Kapeller-Libermann D, Avizonis D, Gutierrez J, Handly-Santana A,
Doubrovin M, Park J, Schoepfer C, et al: eIF4A supports an
oncogenic translation program in pancreatic ductal adenocarcinoma.
Nat Commun. 10:51512019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shaoyan X, Juanjuan Y, Yalan T, Ping H,
Jianzhong L and Qinian W: Downregulation of EIF4A2 in
non-small-cell lung cancer associates with poor prognosis. Clin
Lung Cancer. 14:658–665. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ,
Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, et al: Knockdown of miR-21 in
human breast cancer cell lines inhibits proliferation, in vitro
migration and in vivo tumor growth. 13(R2)2011.
|
|
27
|
Chen ZH, Qi JJ, Wu QN, Lu JH, Liu ZX, Wang
Y, Hu PS, Li T, Lin JF, Wu XY, et al: Eukaryotic initiation factor
4A2 promotes experimental metastasis and oxaliplatin resistance in
colorectal cancer. J Exp Clin Cancer Res. 38:1962019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rice TW, Kelsen DP and Blackstone EH:
Esophagus and Esophagogastric Junction. AJCC Cancer Staging Manual.
8th. Amin MB, Edge SB and Greene FL: New York, NY: Springer; pp.
185–202. 2017, View Article : Google Scholar
|
|
29
|
Dancau AM, Simon R, Mirlacher M and Sauter
G: Tissue microarrays. Methods Mol Biol. 576:49–60. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hinnebusch AG: The scanning mechanism of
eukaryotic translation initiation. Annu Rev Biochem. 83:779–812.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meijer HA, Schmidt T, Gillen SL, Langlais
C, Jukes-Jones R, de Moor CH, Cain K, Wilczynska A and Bushell M:
DEAD-box helicase eIF4A2 inhibits CNOT7 deadenylation activity.
Nucleic Acids Res. 47:8224–8238. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheng YF, Chen HS, Wu SC, Chen HC, Hung
WH, Lin CH and Wang BY: Esophageal squamous cell carcinoma and
prognosis in Taiwan. Cancer Med. 7:4193–4201. 2018. View Article : Google Scholar : PubMed/NCBI
|
